Current treatment of myeloproliferative neoplasias: three scenarios.

作者信息

Xicoy Blanca, Zamora Lurdes

机构信息

Hematología Clínica, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, España.

Laboratorio Hematología, Biología Molecular,, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, España.

出版信息

Med Clin (Barc). 2020 Feb 28;154(4):131-133. doi: 10.1016/j.medcli.2019.05.009. Epub 2019 Jul 24.

DOI:10.1016/j.medcli.2019.05.009

PMID:31351663

Abstract

摘要

相似文献

Current treatment of myeloproliferative neoplasias: three scenarios.

Med Clin (Barc). 2020 Feb 28;154(4):131-133. doi: 10.1016/j.medcli.2019.05.009. Epub 2019 Jul 24.

Off-Target Effects of BCR-ABL and JAK2 Inhibitors.

Am J Clin Oncol. 2016 Feb;39(1):76-84. doi: 10.1097/COC.0000000000000023.

JAK2 inhibitors: not the next imatinib but researchers see other possibilities.

J Natl Cancer Inst. 2009 Jul 15;101(14):980-2. doi: 10.1093/jnci/djp216. Epub 2009 Jul 7.

[Physiopathology, diagnosis and treatment of chronic myeloproliferative diseases: discussion].

Nihon Naika Gakkai Zasshi. 2007 Jul 10;96(7):1434-55. doi: 10.2169/naika.96.1434.

A phase 1 study of the Janus kinase 2 (JAK2) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.

Leuk Res. 2017 Oct;61:89-95. doi: 10.1016/j.leukres.2017.08.010. Epub 2017 Aug 31.

Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.

Leuk Lymphoma. 2016;57(1):201-2. doi: 10.3109/10428194.2015.1037763. Epub 2015 May 12.

The management of elderly patients with myeloproliferative disorders.

Hematol Oncol. 1993;11 Suppl 1:39-41.

Novel therapeutics in myeloproliferative neoplasms.

J Hematol Oncol. 2020 Dec 2;13(1):162. doi: 10.1186/s13045-020-00995-y.

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.

Cancer. 2003 Jun 1;97(11):2760-6. doi: 10.1002/cncr.11416.

Introduction and overview of interferon alfa in myeloproliferative and hemangiomatous diseases.

Semin Hematol. 1990 Jul;27(3 Suppl 4):1-5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Current treatment of myeloproliferative neoplasias: three scenarios.

Med Clin (Barc). 2020 Feb 28;154(4):131-133. doi: 10.1016/j.medcli.2019.05.009. Epub 2019 Jul 24.

Off-Target Effects of BCR-ABL and JAK2 Inhibitors.

Am J Clin Oncol. 2016 Feb;39(1):76-84. doi: 10.1097/COC.0000000000000023.

JAK2 inhibitors: not the next imatinib but researchers see other possibilities.

J Natl Cancer Inst. 2009 Jul 15;101(14):980-2. doi: 10.1093/jnci/djp216. Epub 2009 Jul 7.

[Physiopathology, diagnosis and treatment of chronic myeloproliferative diseases: discussion].

Nihon Naika Gakkai Zasshi. 2007 Jul 10;96(7):1434-55. doi: 10.2169/naika.96.1434.

A phase 1 study of the Janus kinase 2 (JAK2) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.

Leuk Res. 2017 Oct;61:89-95. doi: 10.1016/j.leukres.2017.08.010. Epub 2017 Aug 31.

Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.

Leuk Lymphoma. 2016;57(1):201-2. doi: 10.3109/10428194.2015.1037763. Epub 2015 May 12.

The management of elderly patients with myeloproliferative disorders.

Hematol Oncol. 1993;11 Suppl 1:39-41.

Novel therapeutics in myeloproliferative neoplasms.

J Hematol Oncol. 2020 Dec 2;13(1):162. doi: 10.1186/s13045-020-00995-y.

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.

Cancer. 2003 Jun 1;97(11):2760-6. doi: 10.1002/cncr.11416.

Introduction and overview of interferon alfa in myeloproliferative and hemangiomatous diseases.

Semin Hematol. 1990 Jul;27(3 Suppl 4):1-5.